






Background:	 Proprotein	 convertase	 subtilisin/kexin	 type	 9	 (PCSK9)	 represents	 a	 key-regulator	
pathway	for	hepatic	LDL	receptor	degradation.	Clinical	and	experimental	evidence	 indicates	that	




line	 (HepG2)	 and	 HepG2	 overexpressing	 PCSK9	 (HepG2PCSK9)	 were	 used	 as	 in	 vitro	 tools.	 qPCR,	
Western	 blot,	 ELISA	 and	 luciferase	 reporter	 assays,	 together	with	 siRNA	 directed	 to	 STAT3	 and	
SOCS3,	 were	 used.	 Results:	 HepG2	 expresses	 leptin	 (ObRl)	 and	 resistin	 (adenylyl	 cyclase-
associated	 protein	 1,	 CAP1)	 receptors.	 HepG2PCSK9	 expresses	 higher	 levels	 of	 ObRl	 and	 CAP1.	
Twenty-four	h	treatment	of	HepG2	with	TNF-α	(10	ng/mL),	and		48-h	treatment	with	leptin	(200	
ng/mL)	 and	 resistin	 (50	 ng/mL)	 induced	 the	 expression	 of	 both	 PCSK9	 (2.3-,	 2.0-	 and	 3.5-fold,	
respectively)	 and	 SOCS3	 (3-,	 1.8-	 and	 1.9-fold,	 respectively).	 TNF-α	 and	 leptin	 increased	 the	
secreting	PCSK9	(+15%	and	+20%,	respectively)	but	only	leptin	stimulated	PCSK9	promoter	activity	
(+20%).	 TNF-α,	 leptin	 and	 resistin	 induced	 the	 gene	 expression	 of	 sterol	 regulatory	 element-
binding	 protein	 1	 (SREBP1),	 stearoyl-CoA	 desaturase-1	 (SCD-1),	 fatty	 acid	 synthase	 (FAS)	 and	
microsomal	 triglyceride	 transfer	 protein	 (MTP).	 The	 TNF-α	 mediated	 effects	 were	 inhibited	 by	
transfection	 with	 siRNA	 anti-STAT3,	 suggesting	 the	 involvement	 of	 the	 JAK/STAT	 pathway.	
Conclusions:	 Pro-inflammatory	 cytokines	 and	 adipokines	 up-regulate	 PCSK9	 expression	 and	 the	
key	genes	involved	in	the	de	novo	lipogenesis.	
